Friday 29 Mar 2024
By
main news image
Srividya Gopalakrishnan

While we have seen many sizeable global deals in H1 2016, not all of them may see the light of day as many are still pending regulatory and other approvals, especially after witnessing US$100 billion plus deals such as Pfizer’s acquisition of Allergan getting cancelled due to regulatory issues.

Also, as we see a significant interest from Asian and American companies to acquire UK and European assets during the first half of 2016, we cannot but wonder how the “new normal” Brexit situation will impact these going forward. It will be interesting to see how deal making will shape up for the rest of the year and to what extent restructuring would contribute to the transactions landscape going forward.

 

Srividya Gopalakrishnan
Managing Director
Duff & Phelps

      Print
      Text Size
      Share